Filing Flows › Comparisons › ZBIO vs ZOMDF
Zenas BioPharma vs Zomedica: ZBIO and ZOMDF compared
Zenas BioPharma is the larger company: $10.0M of revenue in its latest quarter (Q3 2026) against $9.9M for Zomedica (Q3 2026).
Where the money goes: ZBIO and ZOMDF
Zenas BioPharma (ZBIO) · Q3 2026
Zenas BioPharma, Q3 2026: revenue $10.0M, net loss $109M, operating cash flow −$58.0M. The chart follows the revenue to costs, profit and cash.
Zomedica (ZOMDF) · Q3 2026
Zomedica, Q3 2026: revenue $9.9M (+22% year over year), operating margin -34.6%, net loss $3.2M, operating cash flow −$2.8M. The chart follows the revenue to costs, profit and cash.
| Zenas BioPharma (ZBIO) | Zomedica (ZOMDF) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $10.0M | $9.9M |
| Revenue growth, Y/Y | — | +22% |
| Operating margin | n/m | -34.6% |
| Net earnings | −$109M | −$3.2M |
| Net margin | — | -32.0% |
| Operating cash flow | −$58.0M | −$2.8M |
Where the revenue comes from
Zomedica
- Consumables: $6.8M (69%)
- Capital: $2.0M (20%)
- Engineering: $981K (10%)
- Other: $116K (1%)
Questions
Which is bigger, Zenas BioPharma or Zomedica?
Zenas BioPharma is the larger company: $10.0M of revenue in its latest quarter (Q3 2026) against $9.9M for Zomedica (Q3 2026).
More: Zenas BioPharma earnings · how Zenas BioPharma makes money · Zomedica earnings · how Zomedica makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 5, 2026; 10-Q filed Nov 4, 2026). Fiscal quarters can end on different dates. Not investment advice.